SHENZHEN, China, May 31, 2012 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the first quarter ended March 31, 2012.
Financial Highlights
For the quarter ended March 31, 2012:
Mr. Fuxiang Zhang, Chief Executive Officer, commented, "While we are making solid progress in growing same store sales, growing our bottom line is proving to be more challenging. The general business environment remains unfavourable, which we endeavor to navigate by implementing strict cost control measures. Nevertheless, the rising labor and rental costs continue to pose challenges to our cost control efforts. In the first quarter of 2012, we continued to streamline our store network through evaluation of store performance and optimization of product offerings. We believe that by further enhancing efficiencies at the store management level, optimizing product offerings, strengthening customer service and conducting innovative marketing activities, we will gain competitive advantages over our peers."
First Quarter Results
During the first quarter of 2012, the Company opened 9 new stores and closed 64 stores which were performing below our expectations. As of March 31, 2012, Nepstar had a total of 2,340 stores in operation.
Revenue for the quarter ended March 31, 2012 increased 1.3% to RMB625.8 million (US$99.4 million), compared to revenue of RMB618.1 million for the same period in 2011.
Same store sales (for 2,258 stores opened before December 31, 2010) for the first quarter of 2012 increased by 4.9% compared to the same period in 2011. This growth was mainly attributable to effective sales promotions carried out in March. It was also partially attributable to robust sales of cough and cold medicines and certain nutritional supplements during an outbreak of flu in southern China in March.
First quarter revenue contribution from prescription drugs was 20.6%, OTC drugs was 39.5%, nutritional supplements was 17.0%, traditional Chinese herbal products was 4.0% and convenience and other products was 18.9%.
Nepstar's portfolio of private label products included 1,914 products as of March 31, 2012. Sales of private label products represented approximately 28.2% of revenue and 40.3% of gross profit for the first quarter of 2012. This compares to approximately 29.8% of revenue contribution and 41.4% of gross profit contribution by private label products during the same period of 2011. The decline of private label products' contribution was mainly due to the introduction of more locally procured pharmaceutical products to better address local customer demand.
First quarter gross profit was RMB291.6 million (US$46.3 million), compared to RMB294.8 million for the same period of 2011. Gross profit margin in the first quarter of 2012 was 46.6%, compared to 47.7% for the same period of 2011. The decrease in gross profit margin was mainly due to the mandatory price cuts on pharmaceuticals by the Chinese government, an increase in revenue contribution by locally procured pharmaceutical products with lower gross profit margin and extensive sales promotions conducted in March.
Sales, marketing and other operating expenses as a percentage of revenue in the first quarter of 2012 decreased to 40.4% from 40.7% in the same period of 2011. This decrease from the same period of last year was primarily due to the growth in same store sales and closure of underperforming stores.
General and administrative expenses as a percentage of revenue in the first quarter of 2012 were 4.8%, compared to 5.1% for the same period of 2011. The decrease was attributable to the Company's stringent cost control policies.
As a result of the factors discussed above, income from operations in the first quarter of 2012 was RMB8.7 million (US$1.4 million), compared to RMB11.8 million in the same period of 2011. Operating margin was 1.4% in the first quarter of 2012.
Interest income for the first quarter of 2012 was RMB5.4 million (US$0.9 million), compared to RMB4.9 million for the same period of 2011. The increase in interest income was mainly due to an increase in deposit interest rates by the Chinese government.
Dividend income from cost method investments was RMB1.4 million (US$0.2 million) for the first quarter of 2012, compared to RMB2.0 million for the same period of 2011. Equity in income of an equity method investee was RMB0.7 million (US$0.1 million) for the first quarter of 2012, compared to RMB1.0 million for the same period of 2011.
Nepstar's effective tax rate was 56.8% for the first quarter of 2012, compared to 46.1% for the same period in 2011. Other than the impact from non-deductible expenses, the relatively high proportion of operating losses of the loss-making subsidiaries, of which full valuation allowances were made on their deferred tax assets, as compared to the net operating results of the Company also attributed to the high effective tax rate noted in the first quarter of 2012.
Net income in the first quarter of 2012 was RMB7.0 million (US$1.1 million), which represented RMB0.07 (US$0.01) basic and diluted earnings per American depositary share ("ADS"). This compares to net income of RMB10.6 million, which represented RMB0.10 basic and diluted earnings per ADS for the same period of 2011.
The total number of outstanding ordinary shares of the Company as of March 31, 2012 was 200.7 million. The weighted average number of ordinary shares in the first quarter of 2012 was 201.6 million. Each ADS represents two ordinary shares of the Company.
As of March 31, 2012, Nepstar's total cash, cash equivalents and bank deposits were RMB958.9 million (US$152.3 million) and its shareholders' equity was RMB1.35 billion (US$213.7 million).
In the first quarter of 2012, net cash flow from operations was RMB0.9 million (US$0.1 million) as compared to RMB1.0 million in the same period of 2011.
On April 27, 2012, Nepstar announced a special cash dividend of US$0.60 per ADS, which represents a total value to shareholders of approximately US$60.2 million. The special dividend was paid on or around May 24, 2012 to shareholders of record as of the close of business on May 7, 2012.
Business Outlook
"We are working diligently to meet the challenges posed by the macro environment and the ongoing healthcare reform, as we move into the second quarter, which is typically considered a slow season for pharmaceutical retail business in China," stated Mr. Zhang. "In addition, recent news coverage of chromium tainted capsules from certain producers in mainland China may also have a negative impact on overall consumer confidence in pharmaceutical and nutritional products in capsule form. We do, however, remain optimistic in our well-established reputation among consumers as a provider of high quality pharmaceutical products. Therefore, we believe the potential adverse impact of the publicity of such and similar incidents on our business will be substantially less than that of our competitors. Despite the ongoing challenges in the general business environment, we remain confident about our overall strategy. We will continue to carry out product optimization and innovative marketing programs to achieve better operating results."
Conference Call Information
The Company will host a conference call, to be simultaneously Web cast, on Thursday , May 31, 2012 at 8:00 a.m. Eastern Time / 8:00 p.m. Beijing Time. Interested parties may participate in the conference call by dialing +1-877-407-9210 (North America) or +1-201-689-8049 (International) approximately five to ten minutes before the call start time. A live Web cast of the conference call will be available on the Nepstar Web site at http://www.nepstar.cn.
A replay of the call will be available shortly after the conclusion of the conference call through June 7, 2012 at 11:59 p.m. Eastern Time or June 8, 2011 at 11:59 a.m. Beijing Time. An archived Web cast of the conference call will be available on the Nepstar website at http://www.nepstar.cn. Interested parties may access the replay by dialing +1-877-660-6853 (North America) or +1-201-612-7415 (International) and entering account number 286 and conference ID number 394085.
About China Nepstar Chain Drugstore Ltd.
China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is China's largest retail drugstore chain based on the number of directly operated stores. As of March 31, 2012, the Company had 2,340 stores across 75 cities, one headquarter distribution center and 16 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmacy services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products including consumables. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the robust economic growth in China and to take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Exchange Rate Information
The United States dollar (US$) amounts disclosed in this press release are presented solely for the convenience of the reader. Translations of amounts from RMB into United States dollars for the convenience of the reader were calculated at the certified exchange rate of US$1.00 = RMB6.2975 on March 31, 2012 as set forth in the H.10 weekly statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted into US$ at that rate on March 31, 2012, or at any other date. The percentages stated are calculated based on RMB amounts.
Contacts
Lucia Qian
China Nepstar Chain Drugstore Ltd.
Vice President, IR
Phone: +86-755-2641-4065
Email: qianrt@nepstar.cn
Dixon Chen
Grayling
Investor Relations
Tel: +1-646-284-9403
Email: dixon.chen@grayling.com
Ivette Almeida
Grayling
Media Relations
Tel: +1-646-284-9455
Email: ivette.almeida@grayling.com
Tables follow
China Nepstar Chain Drugstore Ltd. | |||
Unaudited Condensed Consolidated Statements of Comprehensive Income | |||
(amounts in thousands - except per-share data) | |||
Three-month period ended March 31, | |||
2011 | 2012 | 2012 | |
RMB | RMB | USD | |
Revenue | 618,102 | 625,835 | 99,378 |
Cost of goods sold | (323,255) | (334,257) | (53,078) |
Gross profit | 294,847 | 291,578 | 46,300 |
Sales, marketing and other operating expenses | (251,785) | (252,682) | (40,124) |
General and administrative expenses | (31,258) | (30,239) | (4,802) |
Income from operations | 11,804 | 8,657 | 1,374 |
Interest income | 4,868 | 5,384 | 855 |
Dividend income from cost method investments | 2,000 | 1,404 | 223 |
Equity in income of an equity method investee | 1,020 | 742 | 118 |
Income before income tax expense | 19,692 | 16,187 | 2,570 |
Income tax expense | (9,070) | (9,201) | (1,461) |
Net income attributable to China Nepstar Chain Drugstore Ltd. | 10,622 | 6,986 | 1,109 |
Basic earnings per ordinary share | 0.051 | 0.035 | 0.006 |
Basic earnings per ADS | 0.102 | 0.070 | 0.012 |
Diluted earnings per ordinary share | 0.051 | 0.035 | 0.006 |
Diluted earnings per ADS | 0.102 | 0.070 | 0.012 |
Net income | 10,622 | 6,986 | 1,109 |
Other comprehensive income, net of tax: | |||
Foreign currency translation adjustments | 193 | 26 | 4 |
Comprehensive income attributable to China Nepstar Chain Drugstore Ltd. | 10,815 | 7,012 | 1,113 |
China Nepstar Chain Drugstore Ltd. | |||
Unaudited Condensed Consolidated Balance Sheets | |||
(amounts in thousands) | |||
As of | As of | As of | |
December 31, | March 31, | March 31, | |
2011 | 2012 | 2012 | |
RMB | RMB | USD | |
ASSETS | |||
Current assets | |||
Cash and cash equivalents | 767,885 | 726,909 | 115,428 |
Short-term bank time deposits | 43,000 | 63,000 | 10,004 |
Accounts receivable, net of allowance for doubtful accounts | 102,937 | 102,219 | 16,232 |
Amounts due from related parties | 4,649 | 6,728 | 1,068 |
Prepaid expenses, deposits and other current assets | 122,831 | 144,011 | 22,868 |
Inventories | 437,058 | 429,150 | 68,146 |
Deferred tax assets | 2,009 | 2,402 | 381 |
Total current assets | 1,480,369 | 1,474,419 | 234,127 |
Non-current assets | |||
Long-term bank time deposits | 169,000 | 169,000 | 26,836 |
Property and equipment, net | 141,817 | 136,601 | 21,691 |
Rental deposits | 39,559 | 39,627 | 6,292 |
Cost method investments | 12,638 | 12,638 | 2,007 |
Equity method investment | 36,703 | 37,445 | 5,946 |
Intangible assets, net | 3,087 | 3,033 | 482 |
Goodwill | 51,819 | 51,819 | 8,229 |
Deferred tax assets | 3,151 | 2,681 | 426 |
Deposits for acquisition | 1,000 | - | - |
Accrued interest income | 3,054 | 4,908 | 779 |
Total non-current asset | 461,828 | 457,752 | 72,688 |
Total Assets | 1,942,197 | 1,932,171 | 306,815 |
LIABILITIES AND SHAREHOLDERS' EQUITY | |||
Current liabilities | |||
Accounts payable | 352,386 | 360,579 | 57,257 |
Amounts due to related parties | 18,169 | 25,580 | 4,062 |
Accrued expenses and other payables | 118,121 | 102,423 | 16,264 |
Income tax payable | 28,480 | 22,160 | 3,519 |
Deferred Income | 10,662 | 12,685 | 2,014 |
Total current liabilities | 527,818 | 523,427 | 83,116 |
Non-current liabilities | |||
Deferred income | 17,078 | 18,622 | 2,957 |
Deferred tax liabilities | 12,032 | 12,577 | 1,997 |
Other non-current liabilities | 31,015 | 32,080 | 5,094 |
Total non-current liabilities | 60,125 | 63,279 | 10,048 |
Total liabilities | 587,943 | 586,706 | 93,164 |
Shareholders' equity | |||
Share capital | 161 | 160 | 25 |
Treasury stock | (1,736) | (1,456) | (231) |
Additional paid-in capital | 1,252,232 | 1,236,152 | 196,295 |
Accumulated other comprehensive loss | (41,133) | (41,107) | (6,528) |
Retained earnings | 144,730 | 151,716 | 24,090 |
Total China Nepstar Chain Drugstore Ltd. shareholders' equity | 1,354,254 | 1,345,465 | 213,651 |
Total liabilities and shareholders' equity | 1,942,197 | 1,932,171 | 306,815 |
